DE2323723C2 - - Google Patents
Info
- Publication number
- DE2323723C2 DE2323723C2 DE2323723A DE2323723A DE2323723C2 DE 2323723 C2 DE2323723 C2 DE 2323723C2 DE 2323723 A DE2323723 A DE 2323723A DE 2323723 A DE2323723 A DE 2323723A DE 2323723 C2 DE2323723 C2 DE 2323723C2
- Authority
- DE
- Germany
- Prior art keywords
- dihydroxybenzene
- acid
- salt
- solution
- disulfonic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- NDGUAAJHDUBETK-UHFFFAOYSA-N 1,4-dihydroxycyclohexa-3,5-diene-1,2-disulfonic acid Chemical class OC1=CC(S(O)(=O)=O)C(O)(S(O)(=O)=O)C=C1 NDGUAAJHDUBETK-UHFFFAOYSA-N 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 15
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 11
- -1 alkaline earth metal cation Chemical class 0.000 claims description 11
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 10
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 10
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
- 150000001768 cations Chemical class 0.000 claims description 6
- 150000003973 alkyl amines Chemical class 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 239000000243 solution Substances 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000002253 acid Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 5
- ICYPCIUPMUDVFU-UHFFFAOYSA-N 1,4-dihydroxycyclohexa-3,5-diene-1,2-disulfonic acid;n-ethylethanamine Chemical compound CCNCC.CCNCC.OC1=CC(S(O)(=O)=O)C(O)(S(O)(=O)=O)C=C1 ICYPCIUPMUDVFU-UHFFFAOYSA-N 0.000 description 4
- IYVFNTXFRYQLRP-VVSTWUKXSA-N 2-[3,4-bis(2-hydroxyethoxy)phenyl]-5-hydroxy-7-(2-hydroxyethoxy)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-4h-chromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(OCCO)C=C3OC=2C=2C=C(OCCO)C(OCCO)=CC=2)=O)O1 IYVFNTXFRYQLRP-VVSTWUKXSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- CTLTUPWEUCZSIP-UHFFFAOYSA-N 1,4-dihydroxycyclohexa-2,4-diene-1-sulfonic acid Chemical class OC1=CCC(O)(S(O)(=O)=O)C=C1 CTLTUPWEUCZSIP-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- 230000000055 hyoplipidemic effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000008728 vascular permeability Effects 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- DPPPIVFSKJLJDJ-UHFFFAOYSA-N 1,4-dihydroxycyclohexa-3,5-diene-1,2-disulfonic acid;piperazine Chemical compound C1CNCCN1.C1CNCCN1.OC1=CC(S(O)(=O)=O)C(O)(S(O)(=O)=O)C=C1 DPPPIVFSKJLJDJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- CYTYCFOTNPOANT-UHFFFAOYSA-N Perchloroethylene Chemical group ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- AXZAYXJCENRGIM-UHFFFAOYSA-J dipotassium;tetrabromoplatinum(2-) Chemical compound [K+].[K+].[Br-].[Br-].[Br-].[Br-].[Pt+2] AXZAYXJCENRGIM-UHFFFAOYSA-J 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000003956 methylamines Chemical class 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- SNKQZROJNVIEFC-UHFFFAOYSA-N perchloric acid;piperazine Chemical compound OCl(=O)(=O)=O.C1CNCCN1 SNKQZROJNVIEFC-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229960005141 piperazine Drugs 0.000 description 2
- 229960003506 piperazine hexahydrate Drugs 0.000 description 2
- AVRVZRUEXIEGMP-UHFFFAOYSA-N piperazine;hexahydrate Chemical compound O.O.O.O.O.O.C1CNCCN1 AVRVZRUEXIEGMP-UHFFFAOYSA-N 0.000 description 2
- 229910001487 potassium perchlorate Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- HIFJUMGIHIZEPX-UHFFFAOYSA-N sulfuric acid;sulfur trioxide Chemical compound O=S(=O)=O.OS(O)(=O)=O HIFJUMGIHIZEPX-UHFFFAOYSA-N 0.000 description 2
- 229950011008 tetrachloroethylene Drugs 0.000 description 2
- YXWWGQDGPFNTFR-UHFFFAOYSA-N 1,4-dihydroxycyclohexa-3,5-diene-1,2-disulfonic acid;potassium Chemical compound [K].OC1=CC(S(O)(=O)=O)C(O)(S(O)(=O)=O)C=C1 YXWWGQDGPFNTFR-UHFFFAOYSA-N 0.000 description 1
- CWKVFRNCODQPDB-UHFFFAOYSA-N 1-(2-aminoethylamino)propan-2-ol Chemical compound CC(O)CNCCN CWKVFRNCODQPDB-UHFFFAOYSA-N 0.000 description 1
- VSAZFRKEFQPOIS-UHFFFAOYSA-N 2,5-dihydroxybenzene-1,4-disulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=C(O)C=C1S(O)(=O)=O VSAZFRKEFQPOIS-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 241001539019 Monolene Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KKWDPSOYNDAZDR-UHFFFAOYSA-N N1CCNCC1.OC1(C(C=C(C=C1)O)S(=O)(=O)O)S(=O)(=O)O Chemical compound N1CCNCC1.OC1(C(C=C(C=C1)O)S(=O)(=O)O)S(=O)(=O)O KKWDPSOYNDAZDR-UHFFFAOYSA-N 0.000 description 1
- UMURZOABHVOJFS-UHFFFAOYSA-N OC1(C(C=C(C=C1)O)S(=O)(=O)O)S(=O)(=O)O.C1(=CC=CC=C1)N.C1(=CC=CC=C1)N Chemical compound OC1(C(C=C(C=C1)O)S(=O)(=O)O)S(=O)(=O)O.C1(=CC=CC=C1)N.C1(=CC=CC=C1)N UMURZOABHVOJFS-UHFFFAOYSA-N 0.000 description 1
- HUKRXGSYMIJOBG-UHFFFAOYSA-N OC1(C(C=C(C=C1)O)S(=O)(=O)O)S(=O)(=O)O.CN.CN Chemical compound OC1(C(C=C(C=C1)O)S(=O)(=O)O)S(=O)(=O)O.CN.CN HUKRXGSYMIJOBG-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000016337 monopotassium tartrate Nutrition 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 description 1
- 229940081543 potassium bitartrate Drugs 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009441 vascular protection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH732672A CH550148A (fr) | 1972-05-17 | 1972-05-17 | Procede de preparation de sels d'acides p-dihydroxybenzenedisulfoniques. |
| CH115473A CH558340A (en) | 1973-01-26 | 1973-01-26 | Dihydroxybenzenedisulphonic acid derivs - prepd from dihydroxybenzene - disulphonic acid and base |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2323723A1 DE2323723A1 (de) | 1973-11-29 |
| DE2323723C2 true DE2323723C2 (enrdf_load_stackoverflow) | 1987-08-13 |
Family
ID=25686824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2323723A Granted DE2323723A1 (de) | 1972-05-17 | 1973-05-10 | Verfahren zur herstellung von neuen derivaten der p-dihydroxybenzoldisulfonsaeure |
Country Status (15)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH591437A5 (enrdf_load_stackoverflow) * | 1974-05-08 | 1977-09-15 | Esteve Dr Lab Del Sa | |
| CH550148A (fr) * | 1972-05-17 | 1974-06-14 | Esteve Lab Del Dr Sa | Procede de preparation de sels d'acides p-dihydroxybenzenedisulfoniques. |
| ZA745083B (en) * | 1973-09-11 | 1975-08-27 | Esteve Labor Dr | Process for the preparation of monoesters and diesters of 2,5-dihydroxy-benzene-sulphonic acid |
| CH591438A5 (enrdf_load_stackoverflow) * | 1975-05-16 | 1977-09-15 | Esteve Dr Lab Del Sa | |
| ES2015433A6 (es) * | 1989-08-03 | 1990-08-16 | Esteve Quimica Sa | Procedimientos de preparacion de la sal de piperacina del monotosilato del acido 2,5-dihidroxibencenosulfonico |
| FR2747040B1 (fr) * | 1996-04-03 | 1998-06-26 | Esteve Labor Dr | Derives 2,5-dihydroxybenzenesulfoniques comme medicaments pour normaliser la fonction endotheliale et la fonction sexuelle, et traiter les troubles vasculaires d'origine diabetique ou endotheliale |
| CA2251226C (fr) * | 1996-04-03 | 2007-09-11 | Laboratorios Del Dr. Esteve S.A. | Utilisation des derives 2,5-dihydroxybenzenesulfoniques pour la fabrication de medicaments destines a la normalisation de la fonction endotheliale, pour le traitement de la dysfonction sexuelle et des complications vasculaires du diabete, ainsi que des troubles vasculaires d'origine endotheliale |
| LT5475B (lt) | 2006-04-12 | 2008-02-25 | Laboratorios Del Dr. Esteve, S. A. | 2,5-dihidroksibenzensulfoninių junginių panaudojimas sutrikimų, paremtų no produkcijos susilpnėjimu, gydymui ir/arba edhf funkcijos reguliavimo pablogėjimui |
| WO2009083940A2 (en) | 2008-01-03 | 2009-07-09 | Action Medicines S.L. | Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3547988A (en) * | 1968-02-05 | 1970-12-15 | Eastman Kodak Co | Process for the preparation of dialkali dihydroxybenzene disulfonates |
-
1973
- 1973-01-01 AR AR247787A patent/AR204506A1/es active
- 1973-04-07 ES ES414365A patent/ES414365A1/es not_active Expired
- 1973-05-03 GB GB2114173A patent/GB1419995A/en not_active Expired
- 1973-05-10 DE DE2323723A patent/DE2323723A1/de active Granted
- 1973-05-10 CA CA170,960A patent/CA1024146A/en not_active Expired
- 1973-05-14 YU YU1264/73A patent/YU41547B/xx unknown
- 1973-05-15 NL NLAANVRAGE7306734,A patent/NL179186C/xx active Search and Examination
- 1973-05-15 DD DD170840A patent/DD107025A5/xx unknown
- 1973-05-15 SE SE7306845A patent/SE416729B/xx unknown
- 1973-05-15 RO RO7300074783A patent/RO62887A/ro unknown
- 1973-05-15 PL PL1973162553A patent/PL93785B1/pl unknown
- 1973-05-15 RO RO7383592A patent/RO72544A/ro unknown
- 1973-05-16 FR FR7317709A patent/FR2201888B1/fr not_active Expired
- 1973-05-17 JP JP5419273A patent/JPS5716982B2/ja not_active Expired
- 1973-05-17 CS CS733534A patent/CS194162B2/cs unknown
- 1973-05-17 HU HUEE2140A patent/HU169471B/hu not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NL7306734A (enrdf_load_stackoverflow) | 1973-11-20 |
| FR2201888B1 (enrdf_load_stackoverflow) | 1977-01-21 |
| DE2323723A1 (de) | 1973-11-29 |
| HU169471B (enrdf_load_stackoverflow) | 1976-11-28 |
| RO72544A (ro) | 1981-06-30 |
| PL93785B1 (en) | 1977-06-30 |
| YU41547B (en) | 1987-10-31 |
| SE416729B (sv) | 1981-02-02 |
| NL179186C (nl) | 1986-08-01 |
| CS194162B2 (en) | 1979-11-30 |
| CA1024146A (en) | 1978-01-10 |
| YU126473A (en) | 1982-02-28 |
| DD107025A5 (enrdf_load_stackoverflow) | 1974-07-12 |
| FR2201888A1 (enrdf_load_stackoverflow) | 1974-05-03 |
| ES414365A1 (es) | 1976-02-01 |
| AR204506A1 (es) | 1976-02-12 |
| RO62887A (fr) | 1978-02-15 |
| GB1419995A (en) | 1976-01-07 |
| JPS5716982B2 (enrdf_load_stackoverflow) | 1982-04-08 |
| JPS4941518A (enrdf_load_stackoverflow) | 1974-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2323723C2 (enrdf_load_stackoverflow) | ||
| CH395136A (de) | Verfahren zur Herstellung von Xanthenen oder Thiaxanthenen | |
| DE1695358A1 (de) | Derivate des Tris(hydroxymethyl)aminomethans | |
| DE2309582C3 (de) | Verfahren zur Gewinnung von reinem 7-Dimethylamino-6-desmethyl-6-desoxytetracyclinhydrochlorid aus seinen wäßrigen Rohlösungen und dabei gebildete Komplexverbindung mit Calciumchlorid | |
| DE2253750C3 (de) | Apovincaminsaure-alkylester, Verfahren zu ihrer Herstellung und pharmazeutische | |
| DE2632118C3 (de) | Apovincaminolester und Verfahren zu deren Herstellung und Arzneimittel | |
| DE3538063C2 (enrdf_load_stackoverflow) | ||
| CH641838A5 (de) | Verfahren zur herstellung von lactulose. | |
| DE2148986A1 (de) | Chondroitinschwefelsaeuresalze und ein Verfahren zu ihrer Herstellung | |
| DE2408372C3 (de) | Therapeutisch verträgliche Salze der p-Chlorhippursäure und diese oder p-Chlorhippursäure enthaltende pharmazeutische Zubereitungen | |
| EP0201055B1 (de) | Verfahren zur Herstellung von halogenidfreien quaternären Ammoniumsalzen | |
| DE2511576A1 (de) | Metformin-clofibrat, verfahren zu seiner herstellung und es enthaltendes arzneimittel | |
| DE2827932A1 (de) | Biphenylsulfonyliminoverbindungen | |
| AT225196B (de) | Verfahren zur Herstellung des neuen 2,4-Diamino-1-p-chlorphenyl-6,6-3'-methylpentamethylen-1,6-dihydro-s-triazins und seiner Säureadditionssalze | |
| AT266108B (de) | Verfahren zur Herstellung der neuen 6,7-Dihyroxycumarin-4-methylsulfonsäure und ihrer Salze | |
| DE2839311C2 (de) | Pharmazeutisches Präparat gegen Geschwüre | |
| CH629777A5 (de) | Verfahren zur herstellung von 3-niedrigalkoxy-cyproheptadinen. | |
| AT229313B (de) | Verfahren zur Herstellung von neuen Nikotinoyl- und Isonikotinoyl-mono- und -dibenzylaminen | |
| DE1470157C (de) | 2 Dimethylsulfat!^ 9 eckige Klammer auf 3 (4 methylpiperazino)-propyliden ecki ge Klammer zu thioxanthen, dessen eis/ trans Isomere, deren Salze und Verfahren zur Herstellung dieser Verbindungen | |
| DE2827452A1 (de) | Anionisch substituierte benzoltetrayltetrakis(carbonylimino-tetraisophthalsaeuresalze | |
| AT267512B (de) | Verfahren zur Herstellung von reinem Methdilazinsulfoxyd und seinen Salzen | |
| DE2733056A1 (de) | Vincamenin und seine saeureadditionssalze, quaternaeren vincameniniumsalze und molekuelverbindungen, solche enthaltende arzneimittel sowie verfahren zur herstellung derselben | |
| DE2200589A1 (de) | Beta-pyridylcarbinolnikotinoylglycinat | |
| DE2237732A1 (de) | 1-(3-hydroxystyryl)-pyridiniumsalze und verfahren zu ihrer herstellung | |
| CH633002A5 (de) | Verfahren zur herstellung von komplexen malonylharnstoffderivaten. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| 8127 | New person/name/address of the applicant |
Owner name: PROVESAN S.A., GENF/GENEVE, CH |
|
| 8128 | New person/name/address of the agent |
Representative=s name: VOSSIUS, V., DIPL.-CHEM. DR.RER.NAT. VOSSIUS, D., |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |